Indication
Graft Failure
3 clinical trials
2 products
1 drug
Clinical trial
An Open Label, Single Arm, Multicentre, Proof of Concept, Phase 2 Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After Allogeneic Hematopoietic Stem Cell TransplantationStatus: Terminated, Estimated PCD: 2022-04-21
Product
EmapalumabClinical trial
Wharton's Jelly Mesenchymal Stromal Cell (WG-MSC) Injections as GVHD Prophylaxis in Hematopoietic Allogeneic Stem Cell Transplantation With an Haplo-identical Donor : a Dose Escalation StudyStatus: Not yet recruiting, Estimated PCD: 2025-09-01
Product
WJ-MSC infusionClinical trial
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy ; a Pilot Phase II Study.Status: Recruiting, Estimated PCD: 2024-04-01
Drug
Tocilizumab